Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

  • receive the eCopy two days prior to the printed edition.
  • can partake in our online MCQs.
  • can enter our online sports quiz.


Medicalindependent.ie is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

Irish patients ‘denied access’ to new cancer medicines – IPHA

By Mindo - 09th Aug 2018 | 25 views

<span id=”docs-internal-guid-2372dfcd-7fff-cd83-0dfe-f49df8029e9e”> <p dir=”ltr”><span>The IPHA report claims that seven cancer medicines are available in 12 western European countries but a decision for approval in the Irish system is awaited. Meanwhile, IPHA allege that this places the Government’s target to put Ireland in the top quartile of European countries for cancer survival within the next decade at risk. </span>

<p dir=”ltr”><span>Four of these medicines are for lung cancer. According to the National Cancer Registry, lung cancer was the leading cause of cancer death between 2012 and 2014, accounting for 19 per cent of cancer deaths in women and 23 per cent of cancer deaths in men. </span>

<p dir=”ltr”><span>Ten IPHA medicines for cancer, cardiovascular disease and musculoskeletal treatment are still not on the reimbursement list for approval. These medicines are available in 12 of the 14 EU countries but they are not routinely available and reimbursed for Irish patients. The report revealed that 11 innovative medicines have been approved for reimbursement and are now available to patients.</span>

<p dir=”ltr”><span>IPHA Chief Executive, Mr Oliver O’Connor said “Ireland’s progress in approving innovative medicines for patients remains frustratingly slow, especially for cancer and heart disease.”</span>

<p dir=”ltr”><span>“In this, our second bulletin benchmarking medicines’ availability in Ireland against our peer EU countries, the figures show that we have made no progress since the last quarter. This is very frustrating, both for clinicians and patients, because it shows that Ireland continues to be among the slowest countries in western Europe to be able to access and reimburse innovative medicines.”</span>

<p dir=”ltr”><span>He added : “Our industry is making good on a pledge to limit the prices of our medicines to an average of the prices in 14 EU countries. Since July 2016, there have been three rounds of price cuts for thousands of medicines. By the end of 2020 when our agreement with the Government expires, €785 million in overall savings are expected to have been delivered. But, so far, these savings are not being fully reinvested back into new medicines.”</span>

<br /></span>

Leave a Reply

Latest
Latest Issue
medical news
The Medical Independent 19th May 2022

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read